In October 2010, Sloning BioTechnology GmbH joined the MorphoSys Group. The transaction made MorphoSys the sole source of Sloning's state-of-the-art Slonomics® technology.
Sloning’s superior combinatorial libraries are unbiased and enable researchers to increase the success rate of their screening for new and optimized therapeutic antibodies, proteins or industrial enzymes.
Key to Sloning’s success is the company’s core technology, Slonomics, a proprietary, fully automated genetic engineering platform that utilizes sets of double stranded DNA triplets in the controlled fabrication of highly diverse combinatorial gene libraries.
